Vitagerpavac Herpesvirus Vaccine Description

Vitagerpavac is the only multivalent vaccine in the world for the treatment of chronic herpesvirus infection (HCV) of types I and II.

The vaccine was developed at the Research Institute of Virology. DI. Ivanovsky RAMS and has been used in the Russian Federation for over 15 years.

Vitaherpavac is a dry, inactivated herpes simplex virus (HSV) culture vaccine, that has been obtained, by using the Vero B continuous cell line as a substrate for the accumulation of herpes simplex virus types 1 (US strain) and 2 (VN strain).

The vaccine stimulates body mechanisms of cellular resistance to herpes simplex virus type 1 and type 2.

Approved by the Ministry of Health in the form of guidelines of the Russian Federation MR 3.3.1.0002-10 "Immunization with the" Vitagerpavac "vaccine

Vitagerpavac Herpesvirus Vaccine Indication

This Russian vaccine is indicated to prevent the chronic herpes virus infection of HSV1 and HSV2.  It is indicated for patients with a chronic herpes infection in remission.

Contraindications for vaccination:

active herpes infection (relapse)

acute infectious and non-infectious diseases

chronic diseases in the acute stage

malignant neoplasms

pregnancy

the presence of active symptoms of AIDS

Vitagerpavac Herpesvirus Vaccine Dosage

The vaccination course includes 5 injections carried out at intervals of 7-10 days between injection

Vitagerpavac Herpesvirus Vaccine Availability

The tolerability and therapeutic effectiveness of the vaccine were tested in patients diagnosed as having chronic frequently recurring herpes.

The trials have yielded positive results that suggest that it is expedient to introduce the new vaccine Vitaherpavac into practice to treat chronic recurrent herpetic infection of various localizations. 

This vaccine has only been approved for use in Russia.

Click here for a list of doctor's consultation and medical centers for the vaccine.